Understanding how and why an otherwise ‘tumor-restrictive’ stroma evolves into a ‘tumor-permissive’ stroma. We believe that therapies restoring the tumor restrictive stroma by normalizing ECM turnover are the future of clinical cancer research.
The hallmark of a ‘tumor-permissive’ stroma is a disruption of tissue microarchitecture and altered extracellular matrix (ECM) remodeling. The ECM alterations in the tumor fuels a vicious cycle of stromal dissemination enriching for cancer-associated fibroblast (CAFs), desmoplasia, immunosuppression and epithelial-to-mesenchymal transition leading to poor efficacy of interventions.
A patient-centric approach to evaluate ECM biomarkers in clinical trials with the potential to predict the likelihood of response and elaborate on MoA by monitoring direct or ‘bystander’ effect on the ECM. In contrast to most other liquid biopsies that focus on circulating tumor DNA (ctDNA) or circulating tumor cells (CSCs), at Nordic Bioscience we focus our biomarker efforts on targeting and quantifying post-translational modifications (PTMs) on proteins or peptide fragments in circulation.
Please don't hesitate to contact us if you have any questions or other inquiries.